10-Q: Utah Medical Products Reports Lower Q1 2025 Earnings Due to OEM Sales Decline

Utah Medical Products' Q1 2025 earnings decreased due to a significant drop in OEM sales, particularly to PendoTECH, despite growth in direct sales of NICU devices.

Summary

• Utah Medical Products reported net sales of $9.71 million for Q1 2025, a 14.4% decrease compared to $11.34 million in Q1 2024.
• The decline in sales was primarily attributed to a $1.476 million decrease in OEM sales to PendoTECH, representing 91% of the total sales decline.
• Excluding PendoTECH sales, domestic sales increased by 9%, while sales outside the U.S. decreased by 14% in USD terms.
• The company's gross profit decreased by 18.1% to $5.538 million, with a gross profit margin of 57.0% compared to 59.7% in Q1 2024.
• Operating income decreased by 18.8% to $3.154 million, with an operating income margin of 32.5% compared to 34.2% in Q1 2024.
• Net income decreased by 23.1% to $3.041 million, and earnings per share (diluted) decreased by 16.0% to $0.92.
• The company repurchased 54,267 shares of its stock at an average price of $59.35 during Q1 2025.
• The company's cash and investments balance increased slightly to $83.3 million, despite using cash for share repurchases and dividends.
• Management expects revenues to be consistent with 1Q 2025 during the remainder of the year, so it has projected a similar percentage decline in its Gross Profit Margin for the year as a whole.
• Management believes that the 1Q 2025 operating performance provides a start that is consistent with achieving its financial performance projections for the calendar year 2025, as previously provided in its Year 2024 SEC 10-K Report.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company experienced a decline in sales and earnings, it maintains a strong balance sheet and is taking steps to manage its business effectively. The management's outlook is cautiously optimistic.

Positives

• Direct sales, representing 70% of total domestic sales, were $406 (+11.6%) higher in 1Q 2025 than in 1Q 2024, primarily due to recovery of NICU device sales.
• Domestic Filshie device sales appear to have stabilized compared to recent previous period declines.
• The company's cash and investments balance increased slightly to $83.3 million, despite using cash for share repurchases and dividends.
• The company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.
• UTMDs strong current ratio improved to 22.3 at March 31, 2025 from 19.6 at March 31, 2024.

Negatives

• Net sales decreased by 14.4% to $9.71 million in Q1 2025 compared to $11.34 million in Q1 2024.
• OEM sales to PendoTECH declined by $1.476 million, accounting for 91% of the total sales decline.
• Gross profit margin decreased to 57.0% from 59.7% in the same period last year.
• Operating income margin decreased to 32.5% from 34.2% in the same period last year.
• Net income decreased by 23.1% to $3.041 million.
• Earnings per share (diluted) decreased by 16.0% to $0.92.

Risks

• The company faces the risk of continuing to lose its largest biopharma pressure sensor OEM customer, PendoTECH.
• There is a potential negative impact from geopolitical tariffs on the company's sales to OUS customers.
• The company's future performance is subject to risks and uncertainties, including those described in its Annual Report on Form 10-K.

Future Outlook

Management projects revenues to be consistent with 1Q 2025 during the remainder of the year and expects a similar percentage decline in its Gross Profit Margin for the year as a whole. Objectives for 2025 include exploiting pre-qualified status, leveraging OUS distribution, defending the Filshie Clip System, introducing new products, achieving excellent financial performance, providing cash dividends, making share repurchases, and remaining vigilant for affordable accretive acquisition opportunities.

Management Comments

• Management believes that the 1Q 2025 operating performance provides a start that is consistent with achieving its financial performance projections for the calendar year 2025, as previously provided in its Year 2024 SEC 10-K Report.
• The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.

Industry Context

The medical device industry is subject to various factors, including regulatory changes, technological advancements, and economic conditions. UTMD's performance is affected by competition, supply chain disruptions, and changes in customer demand. The decline in OEM sales to PendoTECH suggests a shift in that customer's strategy or market position, which impacts UTMD's revenue.

Comparison to Industry Standards

• It is difficult to compare UTMD directly to industry standards without knowing the specific segments in which it competes.
• However, a gross profit margin of 57.0% and an operating income margin of 32.5% are generally considered healthy for a medical device company.
• Companies like Medtronic and Stryker typically have gross profit margins in the 60-70% range and operating income margins in the 20-30% range, but these are much larger companies with different product mixes and cost structures.
• Given UTMD's smaller size and focus on niche markets, its margins are competitive.
• The decline in sales and earnings is a concern, but the company's strong cash position and history of profitability provide a buffer.

Legal Proceedings

• UTMD is a party from time to time in litigation incidental to its business.
• Presently, except for Filshie clip product liability lawsuits, there is no litigation or threatened litigation.
• The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results.

Stakeholder Impact

• Shareholders may be concerned about the decline in sales and earnings, but the company's strong cash position and commitment to dividends and share repurchases may provide some reassurance.
• Employees may be affected by the company's efforts to manage costs and improve efficiency.
• Customers may benefit from the company's focus on product development and innovation.

Next Steps

• The company plans to exploit its pre-qualified status to market high-pressure process control transducer configurations directly to biopharmaceutical manufacturers.
• The company intends to continue leveraging OUS distribution and manufacturing synergies.
• The company will focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.
• The company plans to introduce additional products helpful to clinicians through product development.
• The company will continue to achieve excellent overall financial operating performance despite a contraction in revenues.
• The company will utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued.
• The company will remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies.

Key Dates

Keywords

Utah Medical Products, UTMD, medical devices, OEM sales, PendoTECH, financial results, Q1 2025, earnings, revenue, Filshie Clip, stock repurchase, dividends